Prevention of atherosclerosis using NADPH oxidase inhibitors
US5902831A · kind A · utility
7Cited by
0References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 23, 1997 |
| Grant date | May 11, 1999 |
| Priority date | — |
| Expiry date | May 23, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for the prevention and treatment of atherosclerosis and its related diseases in mammals, in which an NADPH oxidase inhibitor is administered, is provided. The NADPH oxidase inhibitor prevents the production of reactive oxygen species upon exposure of endothelial cells to atherogenic LDL levels, thus resulting in decreased endocytosis and vascular hyperpermeability. Preferred NADPH oxidase inhibitors are of the formula: ##STR1## Additionally, there is provided a diagnostic method for predicting risk of a human patient to atherosclerotic-related diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.